The global Super disintegrants market is projected to reach USD 728.65 million by 2027 from USD 434.44 million in 2020, at a CAGR of 7.7 % during the forecast period. The preparation of special blends of Super disintegrants is an important development in the pharmaceutical industry. With these preparations, manufacturers now have access to a variety of Super disintegrants, including co-processed excipients which consist of a combination of synthetic and natural Super disintegrants or several synthetic Super disintegrants or synthetic Super disintegrants with other pharmaceutical excipients. This helps to improve the functioning of drugs due to the quick functioning of the active ingredients. Disintegrants are specially formulated for use in the direct compression method of tablet formulations that removes a number of processing steps used in wet and dry granulation. Orally disintegrating tablets (ODTs) are one of the fastest-growing drug delivery forms using Super disintegrants for direct compression.
Growth in the adoption of novel excipients is also increasingly being supported by a favorable regulatory environment in the developed regions. The International Pharmaceutical Excipients Council (IPEC) has encouraged the development and use of new excipients. The council has developed a novel excipients evaluation procedure as an independent process to decrease the cost and ambiguity related to the use of novel excipients in pharmaceutical formulations. This is expected to increase the demand for Super disintegrants in the pharmaceutical industry.
The traditionally lucrative pharmaceuticals market is becoming challenging from a growth perspective due to the diminishing drug pipeline, government pressures to curtail healthcare costs, and the increasing regulations on innovative products. This is encouraging pharmaceutical manufacturers to move their manufacturing bases closer to high-growth emerging markets. Through this, manufacturers can take advantage of the low-cost manufacturing along with several financial benefits in terms of attractive tax rates and lenient regulatory guidelines for manufacturing in these countries. A number of major excipients manufacturers are either planning capacity expansions of their existing plants in emerging countries or setting up new manufacturing plants in emerging markets such as China and India.
Despite the growing use of excipients in pharmaceuticals, the Super disintegrants industry faces the challenge of meeting the quality expectations of regulators, end users, drug makers, and more importantly, patients. Variations in super disintegrants production affect drug performance along with its critical quality attributes. Supplier-to-supplier or batch-to-batch variations in super disintegrants concentrations affect the excipients-drug interaction, in turn affecting drug efficacy and quality.
Some of the top companies operating in this industry are Ashland Global Holdings Inc., Roquette Frères S.A., FMC Corporation, DFE Pharma, Huber Corporation, Nippon Soda Co., Ltd.
With significant growth in pharmaceutical manufacturing in the past few years, China and India have emerged as high-growth markets for Super disintegrants. Other than APAC countries, Brazil also shows significant growth potential for the Super disintegrants market. A majority of this growth is driven by the significant growth in the healthcare market as well as the pharmaceutical industry in these regions. The low-cost manufacturing advantage, increasing per capita income, and low regulatory stringency are also factors supporting the growth of the Super disintegrants market in these regions.
North America is expected to dominate the overall Super disintegrants market, throughout the forecast period. The market growth is due to factors such as the presence of key players, established healthcare infrastructure, and availability of funding for research and development for advanced drug delivery methods. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth. In this region, the United States has the maximum share due to supportive healthcare policies, the high number of patients, and a developed healthcare market
Growth in the adoption of novel excipients is also increasingly being supported by a favorable regulatory environment in the developed regions. The International Pharmaceutical Excipients Council (IPEC) has encouraged the development and use of new excipients. The council has developed a novel excipients evaluation procedure as an independent process to decrease the cost and ambiguity related to the use of novel excipients in pharmaceutical formulations. This is expected to increase the demand for Super disintegrants in the pharmaceutical industry.
The traditionally lucrative pharmaceuticals market is becoming challenging from a growth perspective due to the diminishing drug pipeline, government pressures to curtail healthcare costs, and the increasing regulations on innovative products. This is encouraging pharmaceutical manufacturers to move their manufacturing bases closer to high-growth emerging markets. Through this, manufacturers can take advantage of the low-cost manufacturing along with several financial benefits in terms of attractive tax rates and lenient regulatory guidelines for manufacturing in these countries. A number of major excipients manufacturers are either planning capacity expansions of their existing plants in emerging countries or setting up new manufacturing plants in emerging markets such as China and India.
Despite the growing use of excipients in pharmaceuticals, the Super disintegrants industry faces the challenge of meeting the quality expectations of regulators, end users, drug makers, and more importantly, patients. Variations in super disintegrants production affect drug performance along with its critical quality attributes. Supplier-to-supplier or batch-to-batch variations in super disintegrants concentrations affect the excipients-drug interaction, in turn affecting drug efficacy and quality.
Some of the top companies operating in this industry are Ashland Global Holdings Inc., Roquette Frères S.A., FMC Corporation, DFE Pharma, Huber Corporation, Nippon Soda Co., Ltd.
With significant growth in pharmaceutical manufacturing in the past few years, China and India have emerged as high-growth markets for Super disintegrants. Other than APAC countries, Brazil also shows significant growth potential for the Super disintegrants market. A majority of this growth is driven by the significant growth in the healthcare market as well as the pharmaceutical industry in these regions. The low-cost manufacturing advantage, increasing per capita income, and low regulatory stringency are also factors supporting the growth of the Super disintegrants market in these regions.
North America is expected to dominate the overall Super disintegrants market, throughout the forecast period. The market growth is due to factors such as the presence of key players, established healthcare infrastructure, and availability of funding for research and development for advanced drug delivery methods. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth. In this region, the United States has the maximum share due to supportive healthcare policies, the high number of patients, and a developed healthcare market
- Aerospace and Defense
- Agriculture
- Automotive and Transportation
- Business and Finance
- Chemical and Materials
- Consumer Goods and Retails
- Electronics and Semiconductor
- Energy and Power
- Food and Beverages
- Machinery and Equipment
- Manufacturing and Construction
- Medical Devices
- Pharmaceuticals and Healthcare
- Service and Software
- Technology, Media and Telecommunications
- Travel and Tourism
